# 2015

Hersonissos, Crete, Greece

I-01 Jae Eun AhnModelling and Simulation of Motor Symptom Measurements in Parkinson’s Disease after L-Dopa AdministrationWednesday 10:45-12:15 |

I-02 Mona AlameddineOptimal phase 2 dose selection based on the relationship between exposure and target occupancyWednesday 10:45-12:15 |

I-03 Hesham Al-SallamiDevelopment of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patientsWednesday 10:45-12:15 |

I-04 Oskar AlskärInterspecies scaling of the integrated glucose insulin modelWednesday 10:45-12:15 |

I-05 Robert AnderssonDose-response-time modelling - Second generation turnover model with integral feedback controlWednesday 10:45-12:15 |

I-06 Yusuke AsaiMathematical modeling by random ordinary differential equations and their numerical schemesWednesday 10:45-12:15 |

I-07 Hyun-moon BackA Mechanistic multicompartmental Pharmacokinetic model for food effect of fenofibrateWednesday 10:45-12:15 |

I-08 Kathryn BallSemi-physiological population pharmacokinetic modelling of renal transporter-mediated clinical drug-drug interactionsWednesday 10:45-12:15 |

I-09 Guillaume BaneyxPopulation PK model describing multiple peaks after a single oral administration of buparlisib in healthy volunteers.Wednesday 10:45-12:15 |

I-10 Charlotte BarkerPopulation pharmacokinetics of benzylpenicillin in neonates in routine careWednesday 10:45-12:15 |

I-11 Christian BartelsRelation of FEV1 to COPD Patient Outcomes: A patient level pooled analysis of COPD clinical trialsWednesday 10:45-12:15 |

I-12 Ana BastosA joint population pharmacokinetic model of total and unbound temocillin serum concentrations in hemodialysis patientsWednesday 10:45-12:15 |

I-13 Stephan BenayLinear compartmental pharmacokinetic models : from continuous-time differential form to discrete time auto-regression with extra inputs. Application to system identification.Wednesday 10:45-12:15 |

I-14 Linnea BergenholmPopulation PKPD modelling of QRS and PR intervals in conscious dogs.Wednesday 10:45-12:15 |

I-15 Aliénor BergèsTime-to-event (TTE) modelling in drug safety evaluation: a case study Wednesday 10:45-12:15 |

I-16 Jan BerkhoutSystems pharmacology modeling describing osteoporotic disease progression in a population of postmenopausal women receiving placebo or alendronateWednesday 10:45-12:15 |

I-17 Marival BermejoLevel A IVIVC for Carbamazepine IR formulations and in vitro dissolution specifications using one-step approachesWednesday 10:45-12:15 |

I-18 Julie BertrandBayesian Variable Selection for high-throughput genetic association analysis in population pharmacokinetics. Wednesday 10:45-12:15 |

I-19 Shanshan BiModel-Based Meta-Analysis (MBMA) for direct-acting antiviral (DAA) agents in the Treatment of Chronic HCVWednesday 10:45-12:15 |

I-20 Andrzej BienczakPopulation Pharmacokinetic/Pharmacogenetic Analysis of Nevirapine in African ChildrenWednesday 10:45-12:15 |

I-21 Konstantinos BiliourisMatVPC: A User-friendly Matlab Tool for the Automatic Construction of Visual Predictive Checks and Quantified Visual Predictive Checks of Systems Pharmacology ModelsWednesday 10:45-12:15 |

I-22 Sofia BirgerssonNew micronized formulation does not affect the population pharmacokinetic properties of artemisinin.Wednesday 10:45-12:15 |

I-23 Henrik Bjugård NybergInfluence of Covariance Step Success on Final Parameter EstimatesWednesday 10:45-12:15 |

I-24 Irina BondarevaPopulation modeling of changes in steady–state pharmacokinetics of carbamazepine (CBZ) due to antiepileptic drug-drug interactions from therapeutic drug monitoring (TDM) dataWednesday 10:45-12:15 |

I-25 Jennifer BonnerBuilding of a virtual paediatric cancer population for physiologically-based pharmacokinetic modelling and simulation in neonates, infants, and childrenWednesday 10:45-12:15 |

I-26 Boram OhkPopulation pharmacokinetics of FimasartanWednesday 10:45-12:15 |

I-27 Elisa BorellaPredictive assessments of pharmacokinetic alterations in subjects with renal diseaseWednesday 10:45-12:15 |

I-28 Jens Markus BorghardtA New Parameterisation to Describe Parallel Absorption Processes After Drug InhalationWednesday 10:45-12:15 |

I-29 Rolien BoschA mechanism-based model is able to simultaneously explain the effect of rhLCAT and HDL mimetics on biomarkers of reverse cholesterol transport Wednesday 10:45-12:15 |

I-30 Marion Bouillon-PichaultLongitudinal Model-Based Meta-Analysis in Type 2 Diabetes: Assessment of link between fasting plasma glucose and Hba1c.Wednesday 10:45-12:15 |

I-31 Karl BrendelHow to consider microdosing data in a population PK analysis?Wednesday 10:45-12:15 |

I-32 Annika BringsModelling and simulation of adverse drug effects on heart rate in the anaesthetized mouse Wednesday 10:45-12:15 |

I-33 Jantine BrusseePopulation modeling of cytochrome P450 mediated drug metabolism and oral absorption in preterm neonates receiving intravenous and oral midazolam in a cross-over studyWednesday 10:45-12:15 |

I-34 Simon BuatoisUsing Item response theory to yield information from the MDS-UPDRS items in Parkinson’s disease clinical trialsWednesday 10:45-12:15 |

I-35 Núria Buil BrunaPopulation PK/PD modelling of the biomarker and progression free survival effects of Lanreotide Autogel in patients with non-functioning gastroenteropancreatic neuroendocrine tumorsWednesday 10:45-12:15 |

I-36 Theresa CainApplication of Simcyp’s R Library Package in Simulation and Prediction of Metoprolol Compliance Using a Single Plasma Concentration SampleWednesday 10:45-12:15 |

I-37 Sophie CalliesDose projection and prediction of PK/PD response - a bench to bedside example for LY drug.Wednesday 10:45-12:15 |

I-38 Elisa CalvierExtrapolation potential of semi-physiological covariate models to newborns: a simulation-based studyWednesday 10:45-12:15 |

I-39 Tim CardilinModelling and Analysis of Tumor Growth Inhibition for Combination Therapy using Tumor Static Concentration CurvesWednesday 10:45-12:15 |

I-40 Letizia CarraraModelling the effect of Sunitinib given alone and in combination with CPT-11 on the tumor growth in xenografted miceWednesday 10:45-12:15 |

I-41 Massimo CellaUse of a TMDD model in the translational development of a BDNF-neutralizing monoclonal antibodyWednesday 10:45-12:15 |

I-42 Dong Woo ChaeMechanistic Modeling of Telmisartan Blood Pressure Lowering Effect in HumanWednesday 10:45-12:15 |

I-43 Pascal ChanuModel-based simulation assessment of Personalized Healthcare strategies. A case for siponimod in multiple sclerosis.Wednesday 10:45-12:15 |

I-44 Aziz ChaouchApproximate prediction percentiles for non-linear mixed effects models with continuous responseWednesday 10:45-12:15 |

I-45 Christophe ChassagnoleModelling Synergistic Immunotherapy Combinations with Virtual TumourWednesday 10:45-12:15 |

I-46 Clarisse ChavanneHow to simulate pediatric pharmacokinetic (PK) exposures using a population PK dataset composed of incomplete age groups.Wednesday 10:45-12:15 |

I-47 Tina ChecchioMixed Effects Analysis of Non-compartmental Pharmacokinetic Parameters of Tofacitinib from 16 Phase 1 Studies.Wednesday 10:45-12:15 |

I-48 Pierre ChelleAssessment of Endogenous Thrombin Potential predictive potential of Thrombin Generation mechanistic models with Hemophilic A patientsWednesday 10:45-12:15 |

I-49 Chunli ChenApplication of the Multistate Tuberculosis Disease Model for Studying Pharmacokinetics and Pharmacodynamics in a Chronic Tuberculosis Mouse ModelWednesday 10:45-12:15 |

I-50 Mohammed Cherkaoui RbatiMechanistic Model to Predict DDIs in the LiverWednesday 10:45-12:15 |

I-51 Manoranjenni ChettyEmerging covariates on the pharmacokinetics of monoclonal antibodies: Do current PBPK models account for the covariates identified in POPPK studies?Wednesday 10:45-12:15 |

I-52 Maxwell ChirehwaModel based evaluation of higher doses of rifampicin using a semi-mechanistic model incorporating auto-induction and saturation of first-pass hepatic extraction Wednesday 10:45-12:15 |

I-53 Jason ChittendenEvaluation of stepwise covariate model selection with Bayesian modelsWednesday 10:45-12:15 |

I-54 Palang ChotsiriPopulation pharmacokinetic and cardiotoxic modelling of the antimalarial drug piperaquineWednesday 10:45-12:15 |

I-55 Steve ChoyModelling the disease progression of diabetes from healthy to overtly diabetic in ZDSD ratsWednesday 10:45-12:15 |

I-56 Eirini ChristodoulouPharmacokinetics of Crocus sativus L. aqueous extract after peros and intravenous administration to C57/BL6J mice Wednesday 10:45-12:15 |

I-57 Laurent ClaretA comparison of two stage and joint tumor growth inhibition-progression free survival modeling approach to simulate clinical outcome in oncologyWednesday 10:45-12:15 |

I-58 Pieter ColinTowards TDM-guided dosing for cefepime in the critically illWednesday 10:45-12:15 |

I-59 Francois CombesPopulation Pharmacodynamic Modeling and Simulation of Anti-Obesity Clinical Trials to Explore Longitudinal Weight LossWednesday 10:45-12:15 |

I-60 Emmanuelle CometsJoint modelling of iron and hepcidin during the menstrual cycleWednesday 10:45-12:15 |

I-61 Ana Margarita Contreras SandovalTowards a platform PK/PD model for an anti-PD-L1 monoclonal antibody through a preclinical syngeneic melanoma mouse model Wednesday 10:45-12:15 |

I-62 Teresa Dalla CostaPopulation analysis of levofloxacin in plasma, lung and prostrate measured by microdialysis in Wistar rats after intravenous and intratracheal administration Wednesday 10:45-12:15 |

I-63 André DallmannDevelopment of a Physiologically-Based Pharmacokinetic Population Model for Pregnant WomenWednesday 10:45-12:15 |

I-64 Adam DarwichGastric emptying and its covariatesWednesday 10:45-12:15 |

I-65 Camila De AlmeidaPKPD-efficacy modelling of AZD9496, a novel oral selective estrogen receptor downregulatorWednesday 10:45-12:15 |

I-66 Pieter De CockPopulation cefazolin pharmacokinetics before, during and after cardiopulmonary bypass in children undergoing cardiac surgeryWednesday 10:45-12:15 |

I-67 Sjoerd De HoogdPopulation pharmacokinetics of morphine and its metabolites M3G and M6G in morbidly obese patients and healthy volunteersWednesday 10:45-12:15 |

I-68 Mailys De Sousa MendesPrediction of human foetal pharmacokinetic profile using transplacental parameters from ex-vivo human placenta perfusion model and pregnancy-Physiologically Based Pharmacokinetic modelsWednesday 10:45-12:15 |

I-69 Elien De ThayeModel-based comparison of modified-release metoprolol formulations in beagle dogs and rabbits Wednesday 10:45-12:15 |

I-70 Femke de VeldeNonlinear absorption pharmacokinetics of amoxicillinWednesday 10:45-12:15 |

I-71 Brenda de WinterPopulation pharmacokinetics of intravenous albuterol in children with status asthmaticusWednesday 10:45-12:15 |

I-72 Willem de WinterA dynamic population PK/PD model to assess the effect of once daily versus twice daily dosing regimens on the relationship between canagliflozin plasma exposure and HbA1c responseWednesday 10:45-12:15 |

I-73 Wilbert de WitteWhat is the influence of diffusion-limited binding on in vivo target occupancy profiles? Wednesday 10:45-12:15 |

I-74 Francesca Del BeneModelling potential drug-drug interaction risks with a combined top-down/bottom-up approachWednesday 10:45-12:15 |

I-76 Paolo DentiPopulation Pharmacokinetics of Ofloxacin in South African childrenWednesday 10:45-12:15 |

I-77 Cheikh DiackAn empirical drug-disease model to characterize the effect of Ranibizumab on disease progression in wet AMD patientsWednesday 10:45-12:15 |